Xiuyu Julie Cong

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 950 citations

Oncology, Phase 2B/3, Afatinib Versus Placebo +9

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su et al. · The Lancet Oncology · 2012 · 402 citations

Advanced Lung Disease, Medicine, Lung Adenocarcinoma +10

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette et al. · The Lancet Oncology · 2015 · 386 citations

Neoadjuvant Therapy, Neck 1, Randomised Phase 3 +10

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Ezra E.W. Cohen, Lisa Licitra, Barbara Burtness et al. · Annals of Oncology · 2017 · 78 citations · Full text

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)

Vera Hirsh, J. Cadranel, Xiuyu Julie Cong et al. · Journal of Thoracic Oncology · 2013 · 77 citations · Full text

Life Benefit, Medicine, Cancer Management +6